AGP Executive Report
Last update: 4 hours agoClinical Trials in Focus: A BEGONIA phase 1b/2 study reports trastuzumab deruxtecan plus durvalumab shrinking tumors in about six in ten women with hormone-receptor-negative, HER2-low metastatic breast cancer, with benefits still ongoing for many. Cardiology Update: The PVI-SHAM-AF trial at ESC Congress 2026 finds catheter ablation for atrial fibrillation did not significantly improve AF-related quality of life versus a sham procedure, even though it reduced AF recurrence. Coronary Care Research: Polish-led VISION-FFR work compares vFFR with optical coherence tomography in chronic coronary syndromes, aiming to better match functional assessment with plaque detail. Health System Watch: New U.S. Medicaid spending data show Poland’s Medicaid “Medicine Services and Procedures” claims rising to $23,574 in 2024 (up 101.3% year-on-year), alongside Warsaw dental services reaching $311,532 in 2024. Public Health Angle: A bird flu report warns backyard bird feeding can spread H5N1, highlighting gaps in wildlife protection as outbreaks expand. Workforce & Access: A Polish-based story highlights a foreign-trained doctor’s path back into medicine after detention and emigration, including Polish language and diploma recognition hurdles.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.